QHSLab (OTCQB: USAQ) Reports Robust Fiscal 2025 Results: Revenue Surge, Margin Expansion, and Debt Reduction

Key Financial Highlights for Investors

• Revenue Growth: QHSLab posted a significant revenue increase for the fiscal year ended December 31, 2025, with revenues rising 26% to \$2,691,741 from \$2,131,926 the previous year.
• Gross Profit and Margin Expansion: Gross profit rose to \$1,810,849 (up from \$1,357,890), with gross margin improving to 67.3% from 63.7%, reflecting a favorable shift towards higher-margin digital health services and improved cost structure.
• Turnaround to Profitability: The Company transitioned to profitability, reporting net income of \$457,417 for 2025, compared to a net loss of \$259,239 in 2024.
• Significant Debt Reduction: Interest expense was reduced to \$237,413 (down from \$465,055), and almost all funded debt was restructured and extinguished. The Company recorded a gain of approximately \$1.15 million from the extinguishment of convertible debt.
• Stronger Balance Sheet: Cash at year-end increased to \$636,157 (from \$157,168), and current liabilities dropped sharply from roughly \$2.4 million to about \$450,000.

Operational Momentum and Segment Performance

• Integrated Service Program (ISP) Drives Growth: The ISP, which provides clinical decision support, digital assessments, workflow, and reimbursement support, saw revenue surge 74% year-over-year to \$1,121,134. This represents ongoing and robust adoption among primary care providers — a critical long-term growth driver.
• Diversification of Revenue Streams: Sales of immunotherapy treatments increased by approximately 19% year-over-year, signaling continued expansion and diversification across diagnostics, therapeutics, and digital health services.
• Broader Healthcare Solutions Portfolio: QHSLab continued to deliver digital health decision-support tools, allergy diagnostics, and allergen immunotherapy services for primary care physicians managing chronic conditions such as anxiety, depression, chronic pain, allergies, and sleep disorders.

Management Commentary and Strategic Outlook

Troy Grogan, President and CEO, emphasized that 2025 was a pivotal year for QHSLab, citing improved revenue, margins, and a dramatically strengthened balance sheet. He underscored the growing adoption of the ISP among primary care providers as a key strategic advantage.

Looking forward to 2026, Grogan highlighted the Company’s focus on expanding its physician network through targeted sales hiring, scaling digital health infrastructure, and reinforcing its positioning as a trusted partner for primary care providers implementing population-based screening and care management programs.

Key Takeaways and Potential Share Price Catalysts

• Accelerating Revenue Growth: The Company’s revenue growth—particularly the 74% surge in ISP revenue—demonstrates strong demand for its digital health solutions and underpins future scalability.
• Margin Expansion and Operating Leverage: The significant improvement in gross margin to 67.3% signals increasing profitability and an optimized cost structure, which may positively influence valuation multiples.
• Transition to Profitability and Reduced Debt: Moving from a net loss to a net profit, combined with debt extinguishment and an improved balance sheet, enhances the Company’s financial flexibility and may boost investor confidence.
• Strengthened Cash Position: The increase in cash reserves and the steep reduction in current liabilities provide a solid foundation for further growth initiatives in 2026.

About QHSLab

QHSLab, Inc. (OTCQB: USAQ) is a digital health infrastructure company serving independent primary care practices with workflow-integrated digital screening, clinical decision support, and care management services. Its platform helps identify and manage underdiagnosed behavioral health and chronic conditions, supporting reimbursable clinical activities inside and outside office visits. QHSLab generates recurring service fees and also operates an allergy diagnostics and treatment line under the AllergiEnd® brand.

For more details, visit: QHSLab Investor Relations

Investor Relations Contact

Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
[email protected]
QHSLab Twitter

Disclaimer: This article is based on the latest QHSLab, Inc. financial disclosures and management commentary. It contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially. Investors should review official filings and consult with financial advisors before making investment decisions. This is not investment advice.

View QHSLab, Inc. Historical chart here